logo-loader
viewImmuPharma PLC

Immupharma chairman details £2.66mln financing and open label extension study

ImmuPharma PLC’s (LON:IMM) chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability.

McCarthy says the six month extension study confirmed its outstanding and robust safety profile.

He also details the subscription agreement with institutional investor, Lanstead Capital, which brought in around £2.66mln.

Quick facts: ImmuPharma PLC

Price: 13.755 GBX

AIM:IMM
Market: AIM
Market Cap: £25.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Immupharma chairman 'delighted' with first significant investment from...

ImmuPharma PLC's (LON:IMM) Tim McCarthy speaks to Proactive London's Andrew Scott following the news of new funding through two specialist US healthcare investors. Up to US$6.3mln is being invested into IMM from an issue of unsecured convertible securities and associated options to L1 Capital...

on 15/6/20

2 min read